Intestinal Polypoid Adenomas Clinical Presentation

1. Lash RH, Genta RM, Schuler CM. Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. J Clin Pathol. 2010 Aug. 63(8):681-6. [Medline].

2. Merrill RM, Anderson AE. Risk-adjusted colon and rectal cancer incidence rates in the United States. Dis Colon Rectum. 2011 Oct. 54(10):1301-6. [Medline].

3. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993 Dec 30. 329(27):1977-81. [Medline].

4. Singh H, Nugent Z, Mahmud SM, Demers AA, Bernstein CN. Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol. 2010 Mar. 105(3):663-73; quiz 674. [Medline].

5. Baxter NN, Sutradhar R, Forbes SS, Paszat LF, Saskin R, Rabeneck L. Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. Gastroenterology. 2011 Jan. 140(1):65-72. [Medline].

6. Brenner H, Chang-Claude J, Seiler CM, Hoffmeister M. Interval cancers after negative colonoscopy: population-based case-control study. Gut. 2012 Nov. 61(11):1576-82. [Medline].

7. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008 Nov 4. 149(9):627-37. [Medline].

8. Lieberman DA, Rex DK, Winawer SJ, et al, for the United States Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012 Sep. 143(3):844-57. [Medline].

9. Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol. 2012 Sep. 27(9):1423-31. [Medline].

10. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000 May. 118(5):829-34. [Medline].

11. Lang M, Berry D, Passecker K, et al. HuR small-molecule inhibitor elicits differential effects in adenomatosis polyposis and colorectal carcinogenesis. Cancer Res. 2017 May 1. 77(9):2424-38. [Medline].

12. Patel SG, Ahnen DJ. Familial colon cancer syndromes: an update of a rapidly evolving field. Curr Gastroenterol Rep. 2012 Oct. 14(5):428-38. [Medline]. [Full Text].

13. Bonadona V, Boniati B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011 Jun 8. 305(22):2304-10. [Medline].

14. Moisio AL, Jarvinen H, Peltomaki P. Genetic and clinical characterisation of familial adenomatous polyposis: a population based study. Gut. 2002 Jun. 50(6):845-50. [Medline]. [Full Text].

15. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med. 2003 Feb 27. 348(9):791-9. [Medline].

16. Woods MO, Younghusband HB, Parfrey PS, et al. The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease. Gut. 2010 Oct. 59(10):1369-77. [Medline]. [Full Text].

17. Wynder EL, Reddy BS. Metabolic epidemiology of colorectal cancer. Cancer. 1974 Sep. 34(3):suppl:801-6. [Medline].

18. Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med. 1999 Jan 21. 340(3):169-76. [Medline].

19. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med. 1990 Dec 13. 323(24):1664-72. [Medline].

20. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med. 2000 Apr 20. 342(16):1149-55. [Medline].

21. Schatzkin A, Mouw T, Park Y, et al. Dietary fiber and whole-grain consumption in relation to colorectal cancer in the NIH-AARP Diet and Health Study. Am J Clin Nutr. 2007 May. 85(5):1353-60. [Medline].

22. Okabayashi K, Ashrafian H, Hasegawa H, et al. Body mass index category as a risk factor for colorectal adenomas: a systematic review and meta-analysis. Am J Gastroenterol. 2012 Aug. 107(8):1175-85; quiz 1186. [Medline].

23. Boyle T, Keegel T, Bull F, Heyworth J, Fritschi L. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst. 2012 Oct 17. 104(20):1548-61. [Medline].

24. Kushi LH, Doyle C, McCullough M, et al; American Cancer Society 2010 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012 Jan-Feb. 62(1):30-67. [Medline].

25. Martinez ME, Marshall JR et al. Colorectal cancer: environmental and lifestyle issues. Kelsen DP, Daly JM, Kern SE, Levin B, Tepper JE, eds. Gastrointestinal Oncology: Principles and Practices. Philadelphia: Lippincott Williams and Wilkins; 2002. 665-83.

26. Giovannucci E, Colditz GA, Stampfer MJ, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. J Natl Cancer Inst. 1994 Feb 2. 86(3):192-9. [Medline].

27. Giovannucci E, Rimm EB, Stampfer MJ, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men. J Natl Cancer Inst. 1994 Feb 2. 86(3):183-91. [Medline].

28. Rigter LS, Kallenberg FG, Bastiaansen B, et al. A case series of intestinal adenomatous polyposis of unidentified etiology; a late effect of irradiation?. BMC Cancer. 2016 Nov 8. 16(1):862. [Medline]. [Full Text].

29. Schatzkin A, Freedman LS, Dawsey SM, Lanza E. Interpreting precursor studies: what polyp trials tell us about large-bowel cancer. J Natl Cancer Inst. 1994 Jul 20. 86(14):1053-7. [Medline].

30. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut. 1982 Oct. 23(10):835-42. [Medline].

31. Kaneko R, Sato Y, An Y, et al. Clinico-epidemiologic study of the metabolic syndrome and lifestyle factors associated with the risk of colon adenoma and adenocarcinoma. Asian Pac J Cancer Prev. 2010. 11(4):975-83. [Medline].

32. Lieberman DA, Prindiville S, Weiss DG, Willett W. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA. 2003 Dec 10. 290(22):2959-67. [Medline].

33. Nguyen SP, Bent S, Chen YH, Terdiman JP. Gender as a risk factor for advanced neoplasia and colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009 Jun. 7(6):676-81.e1-3. [Medline].

34. Lieberman S, Walsh T, Schechter M, et al. Features of patients with hereditary mixed polyposis syndrome caused by duplication of GREM1 and implications for screening and surveillance. Gastroenterology. 2017 Jun. 152(8):1876-80.e1. [Medline].

35. Syngal S, Brand RE, Church JM, et al; American College of Gastroenterology. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015 Feb. 110(2):223-62; quiz 263. [Medline].

36. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg. 2008 Aug. 95(8):1029-36. [Medline].

37. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002 Jun. 50(6):840-4. [Medline].

38. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000 Nov 30. 343(22):1603-7. [Medline].

39. Kronborg O, Jorgensen OD, Fenger C, Rasmussen M. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol. 2004 Sep. 39(9):846-51. [Medline].

40. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007 Feb 20. 146(4):244-55. [Medline].

41. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME, Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004 Dec 23. 351(26):2704-14. [Medline].

42. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008 Oct 7. 149(7):441-50, W81. [Medline].

43. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012 Jun 21. 366(25):2345-57. [Medline].

44. ASGE Standards of Practice Committee, Fisher DA, Maple JT, Ben-Menachem T, et al. Complications of colonoscopy. Gastrointest Endosc. 2011 Oct. 74(4):745-52. [Medline].

45. Singh H, Nugent Z, Demers AA, Bernstein CN. Rate and predictors of early/missed colorectal cancers after colonoscopy in Manitoba: a population-based study. Am J Gastroenterol. 2010 Dec. 105(12):2588-96. [Medline].

46. Cooper GS, Xu F, Barnholtz Sloan JS, Schluchter MD, Koroukian SM. Prevalence and predictors of interval colorectal cancers in medicare beneficiaries. Cancer. 2012 Jun 15. 118(12):3044-52. [Medline].

47. Kahi CJ, Hewett DG, Norton DL, Eckert GJ, Rex DK. Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy. Clin Gastroenterol Hepatol. 2011 Jan. 9(1):42-6. [Medline].

48. Rex DK, Petrini JL, Baron TH, et al. Quality indicators for colonoscopy. Am J Gastroenterol. 2006 Apr. 101(4):873-85. [Medline].

49. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991 Sep. 101(3):635-9. [Medline].

50. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993 May 6. 328(18):1313-6. [Medline].

51. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000 Jun 29. 342(26):1946-52. [Medline].

52. Alfonso-Moreno V, Lopez-Serrano A, Moreno-Osset E. Chemoprevention of polyp recurrence with curcumin followed by silibinin in a case of multiple colorectal adenomas. Rev Esp Enferm Dig. 2017 Dec. 109(12):875. [Medline].

53. Pinsk V, Pinsk I, Ling G, Yerushalmi B, Osyntsov L, Ling E. Complete reversion of familial adenomatous polyposis phenotype associated with tacrolimus and mycophenolate mofetil treatment following kidney transplantation. Anticancer Res. 2017 Jun. 37(6):3105-9. [Medline].

54. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011 Jan 1. 377(9759):31-41. [Medline].

55. Peery AF, Cools KS, Strassle PD, et al. Increasing rates of surgery for patients with non-malignant colorectal polyps in the United States. Gastroenterology. 2018 Jan 6. [Medline].

56. Valentin F, Guarinos C, Juarez M, et al. Endoscopic surveillance in patients with multiple (10-100) colorectal polyps. Endoscopy. 2016 Jan. 48(1):56-61. [Medline].

57. Murphy CJ, Jewel Samadder N, Cox K, et al. Outcomes of next-day versus non-next-day colonoscopy after an initial Inadequate bowel preparation. Dig Dis Sci. 2016 Jan. 61(1):46-52. [Medline].

58. Sourrouille I, Lefevre JH, Shields C, et al. Surveillance of duodenal polyposis in familial adenomatous polyposis: should the Spigelman score be modified?. Dis Colon Rectum. 2017 Nov. 60(11):1137-46. [Medline].

59. Choi JM, Kim SG, Kim J, et al. Clinical implications of pre-existing adenoma in endoscopically resected early gastric cancers. PLoS One. 2017. 12(5):e0178419. [Medline]. [Full Text].

Swati G Patel, MD, MS Clinical Lecturer of Internal Medicine, Division of Gastroenterology, University of Michigan Health System; Staff Physician, Ann Arbor VA Medical Center

Swati G Patel, MD, MS is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Medical Association, American Society for Gastrointestinal Endoscopy, Crohn's and Colitis Foundation of America, Physicians for Human Rights

Disclosure: Nothing to disclose.

Dennis J Ahnen, MD Professor of Medicine, Divisions of Gastroenterology/Medical Oncology, University of Colorado Health Science Center; Consulting Staff, Chief, Gastroenterology Section, Department of Medicine, Veteran's Affairs Medical Center of Denver

Dennis J Ahnen, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Federation for Medical Research, American Gastroenterological Association, Crohn's and Colitis Foundation of America, Gastroenterology Research Group

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cancer Prevention Pharmaceuticals<br/>Serve(d) as a speaker or a member of a speakers bureau for: Ambry Genetics.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Douglas M Heuman, MD, FACP, FACG, AGAF Chief of Hepatology, Hunter Holmes McGuire Department of Veterans Affairs Medical Center; Professor, Department of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University School of Medicine

Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, American Gastroenterological Association

Disclosure: Received grant/research funds from Novartis for other; Received grant/research funds from Bayer for other; Received grant/research funds from Otsuka for none; Received grant/research funds from Bristol Myers Squibb for other; Received none from Scynexis for none; Received grant/research funds from Salix for other; Received grant/research funds from MannKind for other.

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Rajeev Vasudeva, MD Clinical Professor of Medicine, Consultants in Gastroenterology, University of South Carolina School of Medicine

Rajeev Vasudeva, MD is a member of the following medical societies: American College of Gastroenterology, Columbia Medical Society, South Carolina Gastroenterology Association, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, South Carolina Medical Association

Disclosure: Received honoraria from Pricara for speaking and teaching; Received consulting fee from UCB for consulting.

John Riopelle, DO Fellow, Department of Medicine, Division of Gastroenterology/Hepatology, University of Colorado Health Sciences Center

Disclosure: Nothing to disclose.

Alan BR Thomson, MD Professor of Medicine, Division of Gastroenterology, University of Alberta, Canada

Alan BR Thomson, MD is a member of the following medical societies: Alberta Medical Association, American College of Gastroenterology, American Gastroenterological Association, Canadian Association of Gastroenterology, Canadian Medical Association, College of Physicians and Surgeons of Alberta, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of